COL1A1 and systemic sclerosis: In this work, we provide evidence that macitentan (MAC), a novel specific ETAR/ETBR antagonist [21], prevents SSc FB activation induced by TGF-β, blocking protein collagen 1 alpha 1 (Col1A1) production and α-SMA expression.